Cohesion Technologies, Inc.

Collagen Corporation

Other

University of Medicine and Dentistry of New Jersey

Verax Corporation

Incyte Pharmaceuticals, Inc.

Angiotech Pharmaceuticals (us), Inc.

Angiodevice International Gmbh

Pharming Holding N. V.

Pharming B.v.

Medimatrix

Richard A Berg

Woonza M Rhee

Frank A DeLustro

Frederick H Silver

Joel S Rosenblatt

Robert C Dean, Jr

Thomas L Smestad

Jeffrey C Geesin

Philip G Phillips

Peter W Runstadler, Jr

Larry J Braga

Randy W Scott

James M Pachence

Charles J Doillon

Kevin Weadock

Conrad Whyne

Jacqueline A Tefft

Paul David Toman

George H Chu

Donald G Wallace

Abigail Freeman

Jacqueline Anne Schroeder

Gerard Johannes Platenburg

Ronald A Hitzeman

Frank R Pieper

Costas N Karatzas

George E Chisholm, Iv

Barbara M Brodsky

Gregory A Daniels

Kimberly A McCullough

Dan M Jolivette

David E Birk

Frederick A Silver

Gennaro J Maffia

John D'Antonio

Shizuko Tanaka

Eric Eikenberry

Gad Avigad

Ineke De Wit

Manoj Jain

Arkady Chernomorsky

David P Toman

Robert M Olson

Frank A Delustro

Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (&#x2014;NH) or thiol (&#x2014;SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Method for treating or inhibiting the formation of adhesions following surgery or injury

Method for preventing the formation of adhesions following surgery or injury

Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (&#x2014;NH)or thiol (&#x2014;SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymmer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Biocompatible crosslinked composition

Crosslinked polymer compositions

Synthetic implant with nonimmunogenicity coating

Composition for administration of a biologically active compound

The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.

Production of collagen in the milk of transgenic mammals

The invention provides recombinant procollagen chains having a natural collagen chain separated from one or two propeptides by one or two non-natural site-specific proteolytic agent (e.g., protease) recognition sites. A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used: the selection of particular site-specific proteolytic agent/recognition site pairs is based on the conformation of the resulting procollagen, the availability of the site-specific proteolytic agent, the compatibility of the proteolysis with production of mature collagen, among other factors. Recombinant collagens chains are produced by contacting the subject recombinant procollagen chains with the appropriate site-specific proteolytic agents. Nucleic acids encoding the subject procollagen chains operably linked to transcription regulatory elements are used in vectors and cells for the production of recombinant collagen. Such collagen is used in tissue and cell cultureware and therapeutically, such as in biodegradable surgical materials and for tissue augmentation.

Mutated recombinant collagens

Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (&mdash;NH ) or thiol (&mdash;SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Cross-linked polymer compositions and methods for their use

The invention discloses methods for effecting the production of recombinant mammalian procollagen in yeast, as well as compositions comprising yeast cells cap producing mammalian procollagen.

Expression of procollagen in yeast

Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (&mdash;NH,) or thiol (&mdash;SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Method of making crosslinked polymer matrices in tissue treatment applications

The present invention discloses a novel, injectable crosslinked collagen composition which is able to continue crosslinking after injection to a soft or hard tissue site in order to anchor the collagen implant to the host tissue. The composition comprises particulate crosslinked collagen, noncrosslinked collagen (which may be fibrillar or nonfibrillar collagen), and a chemical crosslinking agent, such as synthetic hydrophilic polymer. Methods of augmenting soft or hard tissue using these injectable collagen compositions are also disclosed.

Crosslinked collagen compositions for in situ administration

Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (--NH.sub.2) or thiol (--SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Method of using crosslinked polymer compositions in tissue treatment

Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens.

Production of human recombinant collagen in the milk of transgenic

Crosslinked polymer compositions and methods for their use

Growing community of inventors

Los Altos, CA, United States of America

Richard A Berg